CAR-T CELL THERAPY IN CLL
The treatment paradigm for chronic lymphocytic leukemia (CLL) has shifted dramatically with the FDA approval of lisocabtagene maraleucel (liso-cel) in March 2024. This marks a historic moment as it introduces the first CAR T-cell therapy for CLL, providing renewed hope to patients who have exhausted...
Saved in:
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-12-01
|
Series: | Hematology, Transfusion and Cell Therapy |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2531137924029602 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|